These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30400110)

  • 1. Assessing the sensitivity and specificity of cognitive screening measures for people with Parkinson's disease.
    Foley T; McKinlay A; Warren N; Stolwyk RJ
    NeuroRehabilitation; 2018; 43(4):491-500. PubMed ID: 30400110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
    Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
    Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive screening in Parkinson's disease: Comparison of the Parkinson Neuropsychometric Dementia Assessment (PANDA) with 3 other short scales.
    Gasser AI; Calabrese P; Kalbe E; Kessler J; Rossier P
    Rev Neurol (Paris); 2016 Feb; 172(2):138-45. PubMed ID: 26494570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.
    Phannarus H; Muangpaisan W; Siritipakorn P; Chotinaiwattarakul W
    Psychogeriatrics; 2020 Jan; 20(1):20-27. PubMed ID: 30912230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An assessment of Movement Disorder Society Task Force diagnostic criteria for mild cognitive impairment in Parkinson's disease.
    Uysal-Cantürk P; Hanağası HA; Bilgiç B; Gürvit H; Emre M
    Eur J Neurol; 2018 Jan; 25(1):148-153. PubMed ID: 28941002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Turkish Version of the Montreal Cognitive Assessment Scale (MoCA-TR) in patients with Parkinson's disease.
    Ozdilek B; Kenangil G
    Clin Neuropsychol; 2014; 28(2):333-43. PubMed ID: 24528299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mini-mental Parkinson's (MMP) as a cognitive screening tool in people with Parkinson's disease.
    Caslake R; Summers F; McConachie D; Ferris C; Gordon J; Harris C; Caie L; Counsell C
    Curr Aging Sci; 2013 Dec; 6(3):273-9. PubMed ID: 23773030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease.
    Mahmoudi Asl A; Mehdizadeh M; Kulisevsky J; Sabet A; Taghavi Azar Sharabiani P; Mehdizadeh H; Ashayeri H; Taghizadeh G
    Disabil Rehabil; 2022 May; 44(10):2091-2098. PubMed ID: 32924645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which figure copy test is more sensitive for cognitive impairment in Parkinson's disease: Wire cube or interlocking pentagons?
    Alty JE; Cosgrove J; Jamieson S; Smith SL; Possin KL
    Clin Neurol Neurosurg; 2015 Dec; 139():244-6. PubMed ID: 26519897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease.
    Kaszás B; Kovács N; Balás I; Kállai J; Aschermann Z; Kerekes Z; Komoly S; Nagy F; Janszky J; Lucza T; Karádi K
    Parkinsonism Relat Disord; 2012 Jun; 18(5):553-6. PubMed ID: 22405839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addenbrooke's Cognitive Examination validation in Parkinson's disease.
    Reyes MA; Perez-Lloret S; Roldan Gerschcovich E; Martin ME; Leiguarda R; Merello M
    Eur J Neurol; 2009 Jan; 16(1):142-7. PubMed ID: 19049504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and attempts of revision of the MDS-recommended tests for the screening of Parkinson's disease dementia.
    Isella V; Mapelli C; Siri C; De Gaspari D; Pezzoli G; Antonini A; Poletti M; Bonuccelli U; Vista M; Appollonio IM
    Parkinsonism Relat Disord; 2014 Jan; 20(1):32-6. PubMed ID: 24084382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Italian version of the Parkinson Neuropsychometric Dementia Assessment (PANDA): a useful instrument to detect cognitive impairments in Parkinson's Disease.
    Pignatti R; Bertella L; Scarpina F; Mauro A; Portolani E; Calabrese P
    J Parkinsons Dis; 2014; 4(2):151-60. PubMed ID: 24398655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease.
    van Steenoven I; Aarsland D; Hurtig H; Chen-Plotkin A; Duda JE; Rick J; Chahine LM; Dahodwala N; Trojanowski JQ; Roalf DR; Moberg PJ; Weintraub D
    Mov Disord; 2014 Dec; 29(14):1809-15. PubMed ID: 25381961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of Mini-Mental State Examination, Montreal Cognitive Assessment and Parkinson Neuropsychometric Dementia Assessment in the classification of cognitive performance in Parkinson's disease.
    Scheffels JF; Fröhlich L; Kalbe E; Kessler J
    J Neurol Sci; 2020 May; 412():116735. PubMed ID: 32087430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as cognitive screening measures in Parkinson's disease.
    Brown DS; Bernstein IH; McClintock SM; Munro Cullum C; Dewey RB; Husain M; Lacritz LH
    Int J Geriatr Psychiatry; 2016 Mar; 31(3):264-72. PubMed ID: 26177715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interlocking finger test in patients with Parkinson's disease and healthy subjects.
    Souza CP; Oliveira GN; Foss MP; Tumas V
    J Clin Neurosci; 2016 Jul; 29():145-8. PubMed ID: 26960261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.
    Lucza T; Karádi K; Kállai J; Weintraut R; Janszky J; Makkos A; Komoly S; Kovács N
    Behav Neurol; 2015; 2015():983606. PubMed ID: 26078489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring executive dysfunction in Parkinson's disease: Reliability and validity of the Spanish version of Frontal Assessment Battery (FAB-E).
    Hurtado-Pomares M; Terol-Cantero MC; Sánchez-Pérez A; Leiva-Santana C; Peral-Gómez P; Valera-Gran D; Navarrete-Muñoz EM
    PLoS One; 2018; 13(11):e0207698. PubMed ID: 30452476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosing mild cognitive impairment in Parkinson's disease: which tests perform best in the Italian population?
    Federico A; Trentin M; Zanette G; Mapelli D; Picelli A; Smania N; Tinazzi M; Tamburin S
    Neurol Sci; 2017 Aug; 38(8):1461-1468. PubMed ID: 28550344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.